Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 6/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.49 |
| ▸ | HTR3B | O95264 | 4/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6101358 | 0.94 | CHRNA7 (0.55) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL6098904 | 0.91 | HTR3A (0.49) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL6098756 | 0.88 | CHRNA7 (0.50) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL6099959 | 0.86 | CHRNA7 (0.55) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL6100869 | 0.86 | CHRNA7 (0.50) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL6101655 | 0.85 | HTR3A (0.52) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL6100681 | 0.84 | HTR3A (0.53) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL6100858 | 0.83 | HTR3A (0.52) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL6099969 | 0.82 | CHRNA7 (0.56) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL6098440 | 0.82 | HTR3A (0.53) | HTR3ACHRNA7HTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | HTR3A 3325/4885CHRNA7 1836/4885HTR3E 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.